The Risk Evaluation and Mitigation Strategy (REMS) Public Dashboard: Improving Transparency of Regulatory Activities

被引:0
|
作者
Gita A. Toyserkani
Joann H. Lee
Esther H. Zhou
机构
[1] US Food and Drug Administration (FDA),Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research
来源
Pharmaceutical Medicine | 2023年 / 37卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
This brief paper aims to describe the Risk Evaluation and Mitigation Strategy (REMS) Public Dashboard launched by the US Food and Drug Administration (FDA) in December 2021. The FDA REMS Public Dashboard can be accessed through the REMS@FDA website. The dashboard was developed in Qlik Sense® to support a user-friendly interactive web-based tool that allows healthcare providers, patients, researchers, pharmaceutical companies, and regulators to readily access and visualize REMS information. The dashboard includes eight separate pages to capture information on all REMS, active REMS, REMS with elements to assure safe use, shared system REMS, REMS modifications, REMS revisions, released REMS, and REMS Summary; for REMS programs approved from 2008 to the present. Most of the pages allow users to choose different REMS characteristics to visualize and stratify the data by variables such as REMS approval time, application type, or REMS elements. This interactive platform is intended to allow users to quickly visualize trends over time and locate details of the REMS programs to inform emerging research and regulatory issues in the context of current drug safety. The FDA continues to explore ways to enhance public access of the REMS information in near real-time through the REMS Public Dashboard.
引用
收藏
页码:349 / 353
页数:4
相关论文
共 50 条
  • [21] A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs
    Ameet Sarpatwari
    Mayookha Mitra-Majumdar
    Katsiaryna Bykov
    Jerry Avorn
    Steven Woloshin
    Gita A. Toyserkani
    Cynthia LaCivita
    Claudia Manzo
    Esther H. Zhou
    Ellen Pinnow
    Gerald J. Dal Pan
    Joshua J. Gagne
    Krista F. Huybrechts
    William B. Feldman
    Kristyn Chin
    Aaron S. Kesselheim
    Drug Safety, 2021, 44 : 743 - 751
  • [22] A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs
    Sarpatwari, Ameet
    Mitra-Majumdar, Mayookha
    Bykov, Katsiaryna
    Avorn, Jerry
    Woloshin, Steven
    Toyserkani, Gita A.
    LaCivita, Cynthia
    Manzo, Claudia
    Zhou, Esther H.
    Pinnow, Ellen
    Dal Pan, Gerald J.
    Gagne, Joshua J.
    Huybrechts, Krista F.
    Feldman, William B.
    Chin, Kristyn
    Kesselheim, Aaron S.
    DRUG SAFETY, 2021, 44 (07) : 743 - 751
  • [23] Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program
    Sarpatwari, Ameet
    He, Mengdong
    Tessema, Frazer A.
    Gagne, Joshua J.
    Kesselheim, Aaron S.
    DRUG SAFETY, 2021, 44 (03) : 327 - 335
  • [24] Generalizability of Risk Evaluation and Mitigation Strategies (REMS) Effectiveness Evaluations
    Smith, Danielle J.
    Winterstein, Almut G.
    Willy, Mary
    Karwoski, Claudia
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S223 - S224
  • [25] Assessment of the US food and drug administration's risk evaluation and mitigation strategy (REMS) for prasugrel (effient)
    Metkus, Thomas
    Curran, Jill
    Lin, Shanshan
    Qato, Dima M.
    Alexander, G. Caleb
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 299 - 299
  • [26] Risk Evaluation and Mitigation Strategies (REMS), Pemoline, and What Is a Signal?
    Shader, Richard I.
    CLINICAL THERAPEUTICS, 2017, 39 (04) : 665 - 669
  • [27] Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy
    Sarayani, Amir
    Donahoo, William Troy
    Hampp, Christian
    Brown, Joshua D.
    Winterstein, Almut G.
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (04) : 443 - +
  • [28] The burden of the Risk Evaluation and Mitigation Strategy (REMS) on providers and patients experiencing early pregnancy loss: A commentary
    Flynn, Anne N.
    Shorter, Jade M.
    Roe, Andrea H.
    Sonalkar, Sarita
    Schreiber, Courtney A.
    CONTRACEPTION, 2021, 104 (01) : 29 - 30
  • [29] A Descriptive Evaluation of Prescriber Perceptions and Experience With Risk Evaluation and Mitigation Strategy (REMS) Programs in an Integrated Health Care System
    Nazia Rashid
    T. Craig Cheetham
    Gustavus Aranda
    Valerie N. Guerrero
    Heddy Bartell
    Raymond J. Coghlan
    Therapeutic Innovation & Regulatory Science, 2015, 49 : 503 - 510
  • [30] A Descriptive Evaluation of Prescriber Perceptions and Experience With Risk Evaluation and Mitigation Strategy (REMS) Programs in an Integrated Health Care System
    Rashid, Nazia
    Cheetham, T. Craig
    Aranda, Gustavus, Jr.
    Guerrero, Valerie N.
    Bartell, Heddy
    Coghlan, Raymond J.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (04) : 503 - 510